Blueprint Financial Advisors LLC Buys New Shares in Johnson & Johnson $JNJ

Key Points

• Blueprint Financial Advisors purchased 10,549 Johnson & Johnson shares worth approximately $2.8 million in the third quarter. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported third-quarter EPS of $2.59, exceeding estimates, while revenue rose 5.9% year over year to $25.40 billion. The company also declared a quarterly dividend of $1.34 per share, yielding about 2% annually.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $275.92, but shares trade near their 52-week high at a relatively elevated P/E ratio. MedTech weakness, potential 2027 earnings pressure and ongoing litigation-related headlines remain risks.

Blueprint Financial Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,549 shares of the company's stock, valued at approximately $2,793,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Livelsberger Financial Advisory acquired a new position in Johnson & Johnson during the third quarter valued at $187,000. Cornerstone Wealth LLC TN boosted its holdings in Johnson & Johnson by 6.7% in the third quarter. Cornerstone Wealth LLC TN now owns 1,375 shares of the company's stock valued at $363,000 after purchasing an additional 86 shares during the last quarter. Fonville Wealth Management LLC grew its position in Johnson & Johnson by 111.1% during the 3rd quarter. Fonville Wealth Management LLC now owns 2,145 shares of the company's stock worth $568,000 after purchasing an additional 1,129 shares during the period. Elwood & Goetz Wealth Advisory Group LLC raised its stake in shares of Johnson & Johnson by 13.3% during the 3rd quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 5,537 shares of the company's stock valued at $1,466,000 after buying an additional 652 shares during the last quarter. Finally, Creative Capital Management Investments LLC raised its stake in shares of Johnson & Johnson by 23.2% during the 3rd quarter. Creative Capital Management Investments LLC now owns 383 shares of the company's stock valued at $101,000 after buying an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. Johnson Rice cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. Royal Bank Of Canada dropped their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a report on Wednesday, October 14th. Scotiabank reiterated an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Bank of America reissued a "neutral" rating and issued a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Finally, Erste Group Bank lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $275.92.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $273.39 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business's 50 day moving average price is $265.74 and its 200-day moving average price is $246.94. The firm has a market capitalization of $658.13 billion, a PE ratio of 41.42, a P/E/G ratio of 2.70 and a beta of 0.21. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Insiders Place Their Bets

In other news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 64,515 shares of company stock valued at $17,271,766 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.